Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retlirafusp alfa - Jiangsu Hengrui Medicine

Next Previous
Drug Profile

Retlirafusp alfa - Jiangsu Hengrui Medicine

Alternative Names: SHR 1701

Latest Information Update: 11 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Atridia; Chinese PLA General Hospital; Fudan University; Jiangsu Hengrui Medicine Co.; Suzhou Suncadia Biopharmaceuticals
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cervical cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase II/III Colorectal cancer
  • Phase II Biliary cancer; HER2 negative breast cancer; Malignant melanoma; Pancreatic cancer; Rectal cancer; Squamous cell cancer
  • Phase I/II B-cell lymphoma; Solid tumours
  • No development reported Nasopharyngeal cancer

Most Recent Events

  • 20 Oct 2023 Efficacy and adverse events data from a phase II trial in Malignant melanoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 20 Oct 2023 Efficacy and adverse events data from a phase II/III trial in Colorectal cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 20 Oct 2023 Efficacy and adverse events data from phase Ib/II trial in solid tumours at 48th European Society for Medical Oncology Congress (ESMO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top